Search
Medifoxamine
go.drugbank.com/drugs/DB13219ApprovedMedifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity
Azatadine
go.drugbank.com/drugs/DB00719ApprovedWithdrawnAntihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells.
Categories: Antihistamines for Systemic UseMK-1064
go.drugbank.com/drugs/DB15028InvestigationalMK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).
MK-6325
go.drugbank.com/drugs/DB15249InvestigationalMK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)).
Morphine
go.drugbank.com/drugs/DB00295ApprovedInvestigationalMorphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.
Influenza A virus A/Darwin/9/2021 IVR-228 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB16924ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Synonyms: Influenza A virus A/Darwin/9/2021 IVR-228 (H3N2) antigen (UV, formaldehyde inactivated)Influenza A Virus A/Sydney/5/2021 SAN-013 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB17751ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB17994ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Victoria/4897/2022 IVR-238 (H1N1) Antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB17997ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB19320ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.